Special Issue "Mitochondrial Drugs for Neurodegenerative Diseases"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 August 2012)
Dr. P. Hemachandra Reddy
Neurogenetics Laboratory, Neuroscience Division, Oregon National Primate Research Center, West Campus, Oregon Health and Science University, 505 N.W., 185th Avenue Beaverton, OR 97006, USA
Phone: +1 503 418 2625 (office); +1 503 418 2627 (lab)
Fax: +1 503 418 2501
Interests: aging; neurodegenerative diseases; gene expression analysis; transgenic mouse models; mitochondrial biology; mitochondrial function/dysfunction; mitochondrial therapeutics; mitochondrial dynamics
Mitochondria, cytoplasmic organelles found in virtually every eukaryotic cell, are essential for life and death. In the last two decades tremendous progress has been made in mitochondrial research and has provided significant findings to link mitochondrial dysfunction in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease. Further, recently, several groups developed mitochondrial-targeted antioxidants and tested in cell and mouse models of neurodegenerative diseases. The purpose of this special issue is to assess the current status of mitochondrial therapeutics, particularly mitochondrially targeted molecules in aging and age-related neurodegenerative diseases, and also to discuss the issues related to the development of molecules that cross blood brain barrier, reach mitochondria and protect mitochondria from the toxicity of mutant proteins and other toxic insults.
Prof. Dr. P. Hemachandra Reddy
- Neurodegenerative Disease
- Mitochondrial-targeted antioxidants
- Cyclophilin D
- Mitochondrial permeability pore
- Alzheimer\'s Disease
- Parkinson\'s Disease
- Calcium Dyshomeostasis